HC Wainwright Forecasts Strong Price Appreciation for Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective boosted by HC Wainwright from $130.00 to $158.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 40.44% from the company’s previous close.

DNTH has been the topic of a number of other research reports. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $122.64.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $112.50 on Thursday. The stock’s 50 day simple moving average is $94.02 and its 200 day simple moving average is $79.98. Dianthus Therapeutics has a twelve month low of $18.08 and a twelve month high of $114.55. The company has a market capitalization of $6.15 billion, a price-to-earnings ratio of -27.11 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 25.73%. The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. On average, analysts forecast that Dianthus Therapeutics will post -3.82 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Ryan Savitz sold 31,249 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president owned 31,249 shares in the company, valued at $3,157,086.47. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the transaction, the senior vice president directly owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 87,779 shares of company stock worth $7,985,235. Insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in DNTH. PNC Financial Services Group Inc. increased its position in Dianthus Therapeutics by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after acquiring an additional 139 shares during the period. First Horizon Corp acquired a new stake in Dianthus Therapeutics in the first quarter valued at $32,000. Virtus Investment Advisers LLC increased its holdings in Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after purchasing an additional 416 shares during the period. Royal Bank of Canada raised its position in Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after purchasing an additional 542 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after buying an additional 618 shares during the period. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.